HER2‐negative, node‐positive, high‐risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open‐label, phase 3 trial. Lancet Oncol. 2022;0(0):77‐90.
they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data
阿斯利康全球执行副总裁、肿瘤研发负责人 Susan Galbraith 表示:“DESTINY-Breast06 表明,德曲妥珠单抗可能成为接受一线或二线内分泌治疗后 HER2低表达和 HER2 ultralow极低表达转移性乳腺癌患者的全新治疗新标准。这些数据强调展现了德曲妥珠单抗治疗各种 HR 阳性乳腺癌的潜力,进一步重新定义了转移性乳腺癌的治疗。” 第...
[4]. Twelves C, Bartsch R, Ben-Baruch NE, et al. The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clin Breast Cancer. 2022 Apr;22(3):223-234. doi: 10.1016...
美国真实世界研究揭示HR低阳性、HR中/高阳性、HR阴性HER2阳性MBC的不同特征。在HER2阳性转移性乳腺癌（MBC）患者中，HR阳性与HR阴性肿瘤患者的治疗模式和临床结局存在差异。根据ASCO/CAP指南[1]，区分HR阳性和HR阴性肿瘤的免疫组织化学检测的现有标准阈值为≥1%，HR低阳性（1%-9%肿瘤细胞HR染色阳性）乳腺癌与传统的...
HR+/HER2-早期乳腺癌逐渐进入慢病化管理,患者净获益愈加引发关注,而通过对乳腺癌疾病的全方位随访管理,可帮助患者提高长期净获益,据此,能否谈谈如何通过乳腺癌随诊随访模式探索,以提高患者净获益? 陶思丰教授:在乳腺癌患者随诊随访过程中,除密切监测复发转移外,更应重视乳腺癌各阶段治疗带来的不良反应及伴随疾病,理应...
新药物、新策略不断涌现,如何看待内分泌治疗和化疗在HR+/HER2-晚期乳腺癌中的一线治疗地位。 第二次世界大战时期,氮芥气被当作化学武器应用于战争,后来人们偶然发现它可以杀灭体内的肿瘤细胞,这就是化学治疗的雏形[1]。随着不断涌现的各种化疗药物,化疗发展至今已有近百年的历史,尤其是在乳腺癌领域,化疗一直作为不可...
[2]Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM [3]Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (...
4.Finn RS, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16...
【2】Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial[J]. Journal of Clinical Oncology, 2021, 39(14): 1518-1530. 【3】Martin M, Hegg R, Kim S B, et al. Treatment with adjuvant...